$HRMY
Harmony Biosciences Holdings Inc Stock $hrmy

$hrmy Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000155837024001466 Filed on February 22, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$154.6M	$168.4M	$582.0M
YoY Change	29.79%	31.26%	32.93%
Cost Of Revenue	$27.48M	$43.15M	$121.2M
YoY Change	32.26%	60.51%	45.23%
Gross Profit	$127.1M	$125.3M	$460.8M
YoY Change	29.27%	23.5%	30.03%
Gross Profit Margin	82.22%	74.38%	79.17%
Selling, General & Admin	$52.91M	$54.76M	$192.7M
YoY Change	18.54%	45.03%	18.0%
% of Gross Profit	41.62%	43.72%	41.82%
Research & Development	$22.19M	$30.31M	$76.06M
YoY Change	66.97%	200.3%	7.3%
% of Gross Profit	17.45%	24.19%	16.51%
Depreciation & Amortization	$163.0K	$6.059M	$514.0K
YoY Change	58.25%	-0.15%	22.67%
% of Gross Profit	0.13%	4.84%	0.11%
Operating Expenses	$75.10M	$85.06M	$268.8M
YoY Change	29.65%	58.08%	14.76%
Operating Profit	$52.03M	$40.20M	$192.0M
YoY Change	28.72%	-15.58%	59.78%
Interest Expense	$4.535M	-$700.0K	$23.76M
YoY Change	-271.46%	-80.46%	-251.62%
% of Operating Profit	8.72%	-1.74%	12.37%
Other Income/Expense, Net	-$141.0K	$193.0K	$159.0K
YoY Change	-7150.0%	164.38%	-5.92%
Pretax Income	$51.79M	$39.69M	$173.4M
YoY Change	37.07%	-10.01%	65.63%
Income Tax	$13.45M	$13.08M	$44.54M
% Of Pretax Income	25.97%	32.96%	25.69%
Net Earnings	$38.33M	$26.61M	$128.9M
YoY Change	30.01%	-45.15%	-28.99%
Net Earnings / Revenue	24.79%	15.8%	22.14%
Basic Earnings Per Share	$0.68		$2.17
Diluted Earnings Per Share	$0.67	$0.45	$2.13
COMMON SHARES
Basic Shares Outstanding	56.77M	58.57M	59.47M
Diluted Shares Outstanding	57.60M		60.37M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$372.4M	$353.5M	$353.5M
YoY Change	8.28%	9.39%	9.39%
Cash & Equivalents	$333.0M	$311.7M	$311.7M
Short-Term Investments	$39.37M	$41.80M	$41.80M
Other Short-Term Assets	$8.683M	$5.537M	$18.11M
YoY Change	41.3%	-36.98%	-0.14%
Inventory	$5.857M	$5.363M	$5.363M
Prepaid Expenses	$12.89M	$12.57M
Receivables	$79.72M	$74.14M	$74.14M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$479.5M	$451.1M	$451.1M
YoY Change	14.69%	12.69%	12.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$213.0K	$371.0K	$2.715M
YoY Change	-54.68%	-35.25%	-5.89%
Goodwill
YoY Change
Intangibles	$131.1M	$137.1M
YoY Change	-15.38%	-14.81%
Long-Term Investments	$81.24M	$72.17M	$72.17M
YoY Change	67.38%	219.78%	219.78%
Other Assets	$6.969M	$6.298M	$148.4M
YoY Change	142.82%	125.09%	70.21%
Total Long-Term Assets	$367.5M	$360.4M	$360.4M
YoY Change	23.73%	31.72%	31.72%
TOTAL ASSETS
Total Short-Term Assets	$479.5M	$451.1M	$451.1M
Total Long-Term Assets	$367.5M	$360.4M	$360.4M
Total Assets	$847.0M	$811.4M	$811.4M
YoY Change	18.44%	20.42%	20.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$15.14M	$17.73M	$17.73M
YoY Change	136.11%	368.3%	368.3%
Accrued Expenses	$91.70M	$124.7M	$124.7M
YoY Change	61.41%	108.0%	70.59%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$15.00M	$15.00M	$15.00M
YoY Change	130.77%	650.0%	650.0%
Total Short-Term Liabilities	$154.3M	$163.8M	$163.8M
YoY Change	80.7%	107.62%	107.62%
LONG-TERM LIABILITIES
Long-Term Debt	$175.0M	$178.6M	$178.6M
YoY Change	-5.44%	-5.84%	-5.84%
Other Long-Term Liabilities	$2.342M	$2.109M	$2.109M
YoY Change	44.12%	-15.67%	-15.67%
Total Long-Term Liabilities	$177.3M	$180.7M	$180.7M
YoY Change	-5.01%	-5.97%	-5.97%
TOTAL LIABILITIES
Total Short-Term Liabilities	$154.3M	$163.8M	$163.8M
Total Long-Term Liabilities	$177.3M	$180.7M	$180.7M
Total Liabilities	$331.6M	$344.5M	$344.5M
YoY Change	21.89%	27.09%	27.09%
SHAREHOLDERS EQUITY
Retained Earnings	-$104.9M	-$143.3M
YoY Change	-56.75%	-47.35%
Common Stock	$620.5M	$610.3M
YoY Change	-9.51%	-9.61%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$515.4M	$467.0M	$467.0M
YoY Change
Total Liabilities & Shareholders Equity	$847.0M	$811.4M	$811.4M
YoY Change	18.44%	20.42%	20.42%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	$38.33M	$26.61M	$128.9M
YoY Change	30.01%	-45.15%	-28.99%
Depreciation, Depletion And Amortization	$163.0K	$6.059M	$514.0K
YoY Change	58.25%	-0.15%	22.67%
Cash From Operating Activities	$31.14M	$76.69M	$219.4M
YoY Change	-26.83%	187.45%	51.86%
INVESTING ACTIVITIES
Capital Expenditures	$5.000K	$112.0K	$312.0K
YoY Change			81.4%
Acquisitions			$36.97M
YoY Change
Other Investing Activities	-$6.181M	-$35.93M	-$46.13M
YoY Change	245.31%	-23.39%	-54.63%
Cash From Investing Activities	-$6.186M	-$36.04M	-$46.44M
YoY Change	245.59%	-23.15%	-67.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$100.0M
YoY Change
Debt Paid & Issued, Net	$3.750M		$4.750M
YoY Change	650.0%		137.5%
Cash From Financing Activities	-3.634M	-53.55M	-105.6M
YoY Change	-206.6%	-2114.75%	-1642.93%
NET CHANGE
Cash From Operating Activities	31.14M	76.69M	219.4M
Cash From Investing Activities	-6.186M	-36.04M	-46.44M
Cash From Financing Activities	-3.634M	-53.55M	-105.6M
Net Change In Cash	21.32M	-12.90M	67.40M
YoY Change	-51.74%	-26.51%	611.3%
FREE CASH FLOW
Cash From Operating Activities	$31.14M	$76.69M	$219.4M
Capital Expenditures	$5.000K	$112.0K	$312.0K
Free Cash Flow	$31.14M	$76.58M	$219.1M
YoY Change	-26.84%	187.03%	51.83%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2023	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2022	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2023	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001802665
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2022Q4	us-gaap	Other Receivable After Allowance For Credit Loss Related Party Type Extensible Enumeration OtherReceivableAfterAllowanceForCreditLossRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q4	us-gaap	Other Receivable After Allowance For Credit Loss Related Party Type Extensible Enumeration OtherReceivableAfterAllowanceForCreditLossRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4	us-gaap	Other Liability Related Party Type Extensible Enumeration OtherLiabilityRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q4	us-gaap	Other Liability Related Party Type Extensible Enumeration OtherLiabilityRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2021	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2021	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023	hrmy	Period Of Change In Ownership PeriodOfChangeInOwnership	P3Y
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39450
CY2023	dei	Entity Registrant Name EntityRegistrantName	HARMONY BIOSCIENCES HOLDINGS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-2279923
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	630 W.
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Germantown Pike
CY2023	dei	Entity Address Address Line3 EntityAddressAddressLine3	Suite 215
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Plymouth Meeting
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19462
CY2023	dei	City Area Code CityAreaCode	484
CY2023	dei	Local Phone Number LocalPhoneNumber	539-9800
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.00001 value per share
CY2023	dei	Trading Symbol TradingSymbol	HRMY
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	1174500000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	56769081
CY2023	dei	Auditor Firm AuditorFirmId	34
CY2023	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2023	dei	Auditor Location AuditorLocation	Philadelphia, PA
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	311660000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	243784000
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	41800000
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	79331000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	74140000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	54740000
CY2023Q4	us-gaap	Inventory Net InventoryNet	5363000
CY2022Q4	us-gaap	Inventory Net InventoryNet	4297000
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	12570000
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	9347000
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	5537000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	8786000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	451070000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	400285000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	371000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	573000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	270000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	750000
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	72169000
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	22568000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	137108000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	160953000
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	144162000
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	85943000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6298000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2798000
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	360378000
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	273585000
CY2023Q4	us-gaap	Assets Assets	811448000
CY2022Q4	us-gaap	Assets Assets	673870000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	17730000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3786000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	23747000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11532000
CY2023Q4	hrmy	Accrued Liabilities Other Than Accrued Compensation Current AccruedLiabilitiesOtherThanAccruedCompensationCurrent	99494000
CY2022Q4	hrmy	Accrued Liabilities Other Than Accrued Compensation Current AccruedLiabilitiesOtherThanAccruedCompensationCurrent	59942000
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	15000000
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2000000
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	7810000
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1624000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	163781000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	78884000
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	178566000
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	189647000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2109000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2501000
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	180675000
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	192148000
CY2023Q4	us-gaap	Liabilities Liabilities	344456000
CY2022Q4	us-gaap	Liabilities Liabilities	271032000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	56769081
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	56769081
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	59615731
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	59615731
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1000
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	610266000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	675118000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-151000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-143277000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-272130000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	466992000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	402838000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	811448000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	673870000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	582022000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	437855000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	305440000
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	121236000
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	83481000
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	55518000
CY2023	us-gaap	Gross Profit GrossProfit	460786000
CY2022	us-gaap	Gross Profit GrossProfit	354374000
CY2021	us-gaap	Gross Profit GrossProfit	249922000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	76063000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	70886000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30367000
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	97404000
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	79285000
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	68118000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	95289000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	84017000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	63909000
CY2023	us-gaap	Operating Expenses OperatingExpenses	268756000
CY2022	us-gaap	Operating Expenses OperatingExpenses	234188000
CY2021	us-gaap	Operating Expenses OperatingExpenses	162394000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	192030000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	120186000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	87528000
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-9766000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-26146000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	159000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	169000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	16000
CY2023	us-gaap	Interest Expense InterestExpense	23757000
CY2022	us-gaap	Interest Expense InterestExpense	18795000
CY2021	us-gaap	Interest Expense InterestExpense	24194000
CY2023	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	14730000
CY2022	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	3126000
CY2021	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	224000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	173396000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	104686000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	37428000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	44543000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-76782000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2831000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	128853000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	181468000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	34597000
CY2023	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	153000
CY2022	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-151000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	129006000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	181317000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	34597000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.17
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.07
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.60
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.13
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.97
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.58
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59469648
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59173121
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57531540
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60372397
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61097045
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59205213
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	97180000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	34597000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	29700000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	9371000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15659000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	186507000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	181468000
CY2022	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-151000
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	408000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8433000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	26173000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	402838000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	128853000
CY2023	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	153000
CY2023	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	101097000
CY2023	hrmy	Stock Issued During Period Value Stock Options And Restricted Stock Units Exercised StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercised	4540000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	31705000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	466992000
CY2023	hrmy	Shares Repurchased Excise Tax Rate SharesRepurchasedExciseTaxRate	0.01
CY2023	us-gaap	Profit Loss ProfitLoss	128853000
CY2022	us-gaap	Profit Loss ProfitLoss	181468000
CY2021	us-gaap	Profit Loss ProfitLoss	34597000
CY2023	us-gaap	Depreciation Depreciation	514000
CY2022	us-gaap	Depreciation Depreciation	419000
CY2021	us-gaap	Depreciation Depreciation	416000
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	23845000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	22966000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	18424000
CY2023	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	2260000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	31705000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	26173000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	15659000
CY2023	hrmy	Stock Appreciation Rights Market Adjustment StockAppreciationRightsMarketAdjustment	-499000
CY2022	hrmy	Stock Appreciation Rights Market Adjustment StockAppreciationRightsMarketAdjustment	732000
CY2021	hrmy	Stock Appreciation Rights Market Adjustment StockAppreciationRightsMarketAdjustment	446000
CY2023	hrmy	Adjustment For Amortization Of Debt Issuance Costs AdjustmentForAmortizationOfDebtIssuanceCosts	2274000
CY2022	hrmy	Adjustment For Amortization Of Debt Issuance Costs AdjustmentForAmortizationOfDebtIssuanceCosts	1663000
CY2021	hrmy	Adjustment For Amortization Of Debt Issuance Costs AdjustmentForAmortizationOfDebtIssuanceCosts	2238000
CY2023	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-13419000
CY2022	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-85943000
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2715000
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	432000
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-9766000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-26146000
CY2023	us-gaap	Other Noncash Expense OtherNoncashExpense	1768000
CY2022	us-gaap	Other Noncash Expense OtherNoncashExpense	1526000
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	19400000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	19897000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	12667000
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1066000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-135000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	609000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-74000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7548000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1655000
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	8949000
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	2785000
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-1555000
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	46479000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	20570000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	17263000
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-1000
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-151000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-146000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	219387000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	144466000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	98557000
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	127469000
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	110729000
CY2023	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	118309000
CY2022	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	9069000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	312000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	172000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	298000
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	36967000
CY2022	hrmy	Cash Paid For Milestones CashPaidForMilestones	40000000
CY2021	hrmy	Cash Paid For Milestones CashPaidForMilestones	100000000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-46439000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-141832000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-100298000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	30000000
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	300000
CY2023	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	200000000
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	200000000
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	2997000
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	9152000
CY2023	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	196500000
CY2021	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	200000000
CY2023	hrmy	Payments Of Extinguishment Of Debt Exit Fees PaymentsOfExtinguishmentOfDebtExitFees	5846000
CY2021	hrmy	Payments Of Extinguishment Of Debt Exit Fees PaymentsOfExtinguishmentOfDebtExitFees	22000000
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	4750000
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2000000
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	500000
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	100000000
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	514000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5055000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	8841000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9371000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-105552000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6841000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7419000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	67396000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9475000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5678000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	244534000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	235059000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	229381000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	311930000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	244534000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	235059000
CY2023	us-gaap	Interest Paid Net InterestPaidNet	20051000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	16364000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	19830000
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	48233000
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	12645000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2875000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-143277000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-272130000
CY2023Q4	us-gaap	Investments And Cash InvestmentsAndCash	425629000
CY2023	hrmy	Number Of Approved Commercial Products NumberOfApprovedCommercialProducts	1
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 40pt;"><b style="font-style:normal;font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures in the consolidated financial statements, including the notes thereto, and elsewhere in this report. Actual results may differ significantly from estimates, which include rebates due pursuant to commercial and government contracts, accrued research and development expenses, stock-based compensation expense and income taxes.</p>
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	311660000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	243784000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	270000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	750000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	311930000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	244534000
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 38pt;"><b style="font-style:normal;font-weight:bold;">Concentrations of Risk</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Substantially all of the Company’s cash and money market funds are held in five financial institutions. Due to their size, the Company believes these financial institutions represent minimal credit risk. Deposits may exceed the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation for U.S. institutions. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company believes that it is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to credit risk from its trade receivables related to its product sales. The Company extends credit to specialty pharmaceutical distribution companies within the United States. Customer creditworthiness is monitored and collateral is not required. Historically, the Company has not experienced credit losses on its accounts receivable. The Company monitors its exposure within accounts receivable and would record a reserve against uncollectible accounts receivable if necessary. As of December 31, 2023, three customers accounted for 100% of gross accounts receivable, Accredo Health Group, Inc. (“Accredo”), which accounted for 39% of gross accounts receivable; Caremark LLC (“CVS Caremark”), which accounted for 32% of gross accounts receivable; and PANTHERX Specialty Pharmacy LLC (“Pantherx), which accounted for 29% of gross accounts receivable. As of December 31, 2022, three customers accounted for 100% of gross accounts receivable; CVS Caremark, which accounted for 41% of gross accounts receivable, Accredo, which accounted for 35% of gross accounts receivable and Pantherx, which accounted for 24% of gross accounts receivable.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">For the year ended December 31, 2023, three customers accounted for 100% of gross product revenue; CVS Caremark accounted for 37% of gross product revenue; Accredo accounted for 32% of gross product revenue; and Pantherx accounted for 31% of gross product revenue. For the year ended December 31, 2022, three customers accounted for 100% of gross product revenue; CVS Caremark accounted for 42% of gross product revenue; Pantherx accounted for 29% of gross product revenue; and Accredo accounted for 29% of gross product revenue. For the year ended December 31, 2021, </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">three customers accounted for 100% of gross product revenue; CVS Caremark accounted for 36% of gross product revenue; Pantherx accounted for 35% of gross products revenue; and Accredo accounted for 29% of gross product revenue.</p>
CY2023	hrmy	Concentrations Of Risk Number Of Financial Institutions ConcentrationsOfRiskNumberOfFinancialInstitutions	5
CY2023	us-gaap	Advertising Expense AdvertisingExpense	21544000
CY2022	us-gaap	Advertising Expense AdvertisingExpense	22428000
CY2021	us-gaap	Advertising Expense AdvertisingExpense	19558000
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2022Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0
CY2023Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	358538000
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	286876000
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1060000
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	838000
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	2020000
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1513000
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2283000
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2565000
CY2023Q4	us-gaap	Inventory Gross InventoryGross	5363000
CY2022Q4	us-gaap	Inventory Gross InventoryGross	4916000
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	619000
CY2023Q4	us-gaap	Inventory Net InventoryNet	5363000
CY2022Q4	us-gaap	Inventory Net InventoryNet	4297000
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	23845000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	22966000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	18424000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	23845000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	23845000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	23845000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	23845000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	23845000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	17883000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	137108000
CY2023Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	215000000
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	215000000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	77892000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	54047000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	137108000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	160953000
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	40419000
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	25367000
CY2023Q4	hrmy	Accrued Rebates And Other Sales Deductions Current AccruedRebatesAndOtherSalesDeductionsCurrent	38842000
CY2022Q4	hrmy	Accrued Rebates And Other Sales Deductions Current AccruedRebatesAndOtherSalesDeductionsCurrent	27860000
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	3354000
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	3286000
CY2023Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	2354000
CY2022Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	1135000
CY2023Q4	hrmy	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	9835000
CY2022Q4	hrmy	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	358000
CY2023Q4	hrmy	Accrued Professional Fees Consulting And Other Services AccruedProfessionalFeesConsultingAndOtherServices	2195000
CY2022Q4	hrmy	Accrued Professional Fees Consulting And Other Services AccruedProfessionalFeesConsultingAndOtherServices	1163000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2495000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	773000
CY2023Q4	hrmy	Accrued Liabilities Other Than Accrued Compensation Current AccruedLiabilitiesOtherThanAccruedCompensationCurrent	99494000
CY2022Q4	hrmy	Accrued Liabilities Other Than Accrued Compensation Current AccruedLiabilitiesOtherThanAccruedCompensationCurrent	59942000
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	196250000
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	197500000
CY2023Q4	hrmy	Unamortized Debt Discount Associated With Exit Fee Debt Financing Costs And Discount With Warrant Financing UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing	2684000
CY2022Q4	hrmy	Unamortized Debt Discount Associated With Exit Fee Debt Financing Costs And Discount With Warrant Financing UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing	5853000
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	193566000
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	191647000
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	15000000
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2000000
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	178566000
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	189647000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	15000000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	16250000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	20000000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	20000000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	125000000
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	196250000
CY2023	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	20511000
CY2022	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	17132000
CY2021	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	21955000
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	3246000
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1663000
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2238000
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	23757000
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	18795000
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	24193000
CY2018Q2	hrmy	Operating Lease Office Space OperatingLeaseOfficeSpace	15000
CY2018Q2	hrmy	Operating Lease Additional Office Space Leased One OperatingLeaseAdditionalOfficeSpaceLeasedOne	13000
CY2018Q2	hrmy	Operating Lease Additional Office Space Leased Two OperatingLeaseAdditionalOfficeSpaceLeasedTwo	7000
CY2023	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2023	us-gaap	Lessee Operating Lease Existence Of Option To Terminate LesseeOperatingLeaseExistenceOfOptionToTerminate	true
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	1811000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1526000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0673
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2344000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2312000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1437000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1614000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1082000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	975000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2519000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2589000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	2016000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1716000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2163000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	485000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1550000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	732000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	425000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2707000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	188000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2519000
CY2023Q4	hrmy	Common Stock Number Of Votes Per Share CommonStockNumberOfVotesPerShare	1
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6460947
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	30.90
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M9D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	440294
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	34.80
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	371896
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	12.00
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	212923
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	25.25
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6316422
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	32.47
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M1D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7487
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.8078
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7257
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.7708
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0342
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0462
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0199
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0405
CY2023	hrmy	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Lack Of Marketability Discount ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount	0.0000
CY2022	hrmy	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Lack Of Marketability Discount ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount	0.0000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31206000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	26905000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16105000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31206000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	26905000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16105000
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	69594000
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M18D
CY2023	us-gaap	Net Income Loss NetIncomeLoss	128853000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	181468000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	34597000
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	128853000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	181468000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	34597000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.17
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.07
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.60
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.13
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.97
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.58
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59469648
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59173121
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57531540
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60372397
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61097045
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59205213
CY2023	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	902749
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1923924
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1536825
CY2021	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	136848
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.004
CY2023	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	902749
CY2022	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1923924
CY2021	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1673673
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	31084000
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	10011000
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	6487000
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	11884000
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	9573000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2852000
CY2023	hrmy	Valuation Allowance Income Tax Expense Benefit ValuationAllowanceIncomeTaxExpenseBenefit	1575000
CY2022	hrmy	Valuation Allowance Income Tax Expense Benefit ValuationAllowanceIncomeTaxExpenseBenefit	-96366000
CY2021	hrmy	Valuation Allowance Income Tax Expense Benefit ValuationAllowanceIncomeTaxExpenseBenefit	-6508000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	44543000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-76782000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2831000
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	57962000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	9161000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2831000
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-14994000
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	10423000
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	6508000
CY2023	hrmy	Valuation Allowance Income Tax Expense Benefit ValuationAllowanceIncomeTaxExpenseBenefit	1575000
CY2022	hrmy	Valuation Allowance Income Tax Expense Benefit ValuationAllowanceIncomeTaxExpenseBenefit	-96366000
CY2021	hrmy	Valuation Allowance Income Tax Expense Benefit ValuationAllowanceIncomeTaxExpenseBenefit	-6508000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	44543000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-76782000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2831000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.049
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.023
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.057
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.141
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.064
CY2023	hrmy	Effective Income Tax Rate Reconciliation Credits EffectiveIncomeTaxRateReconciliationCredits	-0.021
CY2022	hrmy	Effective Income Tax Rate Reconciliation Credits EffectiveIncomeTaxRateReconciliationCredits	-0.048
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.009
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.003
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.006
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.702
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.173
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.257
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.733
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.076
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	35337000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	45938000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	45917000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6370000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	19915000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	11551000
CY2023Q4	hrmy	Deferred Tax Liabilities Lease Obligations Net DeferredTaxLiabilitiesLeaseObligationsNet	6000
CY2022Q4	hrmy	Deferred Tax Assets Lease Obligations Net DeferredTaxAssetsLeaseObligationsNet	71000
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	173000
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	115000
CY2023Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	5344000
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	6781000
CY2023Q4	hrmy	Deferred Tax Assets Accrued Rebates DeferredTaxAssetsAccruedRebates	3791000
CY2022Q4	hrmy	Deferred Tax Assets Accrued Rebates DeferredTaxAssetsAccruedRebates	7118000
CY2023Q4	hrmy	Deferred Tax Assets Research And Development DeferredTaxAssetsResearchAndDevelopment	38799000
CY2022Q4	hrmy	Deferred Tax Assets Research And Development DeferredTaxAssetsResearchAndDevelopment	8802000
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1132000
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	790000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	15000
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	818000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	150408000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	796000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	86761000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	818000
CY2023Q4	hrmy	Deferred Tax Assets Liabilities Net Before Valuation Allowance DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance	149612000
CY2022Q4	hrmy	Deferred Tax Assets Liabilities Net Before Valuation Allowance DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance	85943000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5450000
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	144162000
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	85943000
CY2022	hrmy	Tax Benefit Release Of Valuation Allowance TaxBenefitReleaseOfValuationAllowance	96336000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	96366000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	102874000
CY2022	hrmy	Deferred Tax Asset Valuation Allowance Benefit To Income Tax Provision DeferredTaxAssetValuationAllowanceBenefitToIncomeTaxProvision	96366000
CY2021	hrmy	Deferred Tax Asset Valuation Allowance Benefit To Income Tax Provision DeferredTaxAssetValuationAllowanceBenefitToIncomeTaxProvision	6508000
CY2023	hrmy	Deferred Tax Asset Valuation Allowance Increase Acquisition DeferredTaxAssetValuationAllowanceIncreaseAcquisition	3875000
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1575000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5450000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	96366000
CY2023	hrmy	Percentage Of Change In Ownership PercentageOfChangeInOwnership	0.50
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	2128000
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1705000
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	2479000
CY2021Q3	hrmy	Related Party Transaction Payment For Advisory Fee RelatedPartyTransactionPaymentForAdvisoryFee	2300000
CY2022Q4	us-gaap	Other Liabilities OtherLiabilities	0
CY2023Q4	us-gaap	Other Liabilities OtherLiabilities	0
CY2022Q4	us-gaap	Other Receivables OtherReceivables	0
CY2023Q4	us-gaap	Other Receivables OtherReceivables	0
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001558370-24-001466-index-headers.html	Edgar Link	pending
0001558370-24-001466-index.html	Edgar Link	pending
0001558370-24-001466.txt	Edgar Link	pending
0001558370-24-001466-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
hrmy-20231231.xsd	Edgar Link	pending
hrmy-20231231x10k.htm	Edgar Link	pending
hrmy-20231231x10k005.jpg	Edgar Link	pending
hrmy-20231231x10k006.jpg	Edgar Link	pending
hrmy-20231231x10k007.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
hrmy-20231231xex21d1.htm	Edgar Link	pending
hrmy-20231231xex23d1.htm	Edgar Link	pending
hrmy-20231231xex31d1.htm	Edgar Link	pending
hrmy-20231231xex31d2.htm	Edgar Link	pending
hrmy-20231231xex32d1.htm	Edgar Link	pending
hrmy-20231231xex32d2.htm	Edgar Link	pending
hrmy-20231231xex97d1.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
hrmy-20231231_def.xml	Edgar Link	unprocessable
hrmy-20231231_lab.xml	Edgar Link	unprocessable
hrmy-20231231_pre.xml	Edgar Link	unprocessable
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
hrmy-20231231_cal.xml	Edgar Link	unprocessable
hrmy-20231231x10k_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HRMY
Harmony Biosciences Holdings Inc Stock $hrmy

2024 Q1 Form 10-K Financial Statement

#000155837024001466 Filed on February 22, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HRMY Harmony Biosciences Holdings Inc Stock $hrmy

2024 Q1 Form 10-K Financial Statement

#000155837024001466 Filed on February 22, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HRMY
Harmony Biosciences Holdings Inc Stock $hrmy